Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of NK510 in the treatment of Osteosarcoma
and Soft Tissue Sarcoma.NK510 will be administered by intravenous injection. The safety and
efficacy of this treatment will be evaluated.
Phase:
Early Phase 1
Details
Lead Sponsor:
Base Therapeutics (Shanghai) Co., Ltd.
Collaborator:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine